retatrutide
Retatrutide, explained.
Retatrutide is an investigational triple-receptor agonist studied in clinical trials and not approved by any regulator. PepEasy is a neutral place to understand what it is, how it's classified, and what the published research describes.
Educational only — not medical advice. Consult a qualified licensed provider.
Retatrutide (Eli Lilly code LY3437943) is an investigational once-weekly injectable peptide that activates three receptors — GIP, GLP-1, and glucagon. It has been studied in clinical research on obesity and type 2 diabetes. It is not FDA-approved and remains in clinical trials, so material sold under its name is unapproved and typically labeled research-only.
What retatrutide is
Retatrutide is an investigational peptide developed by Eli Lilly under the code name LY3437943. It belongs to the incretin family — the same broad class as semaglutide and tirzepatide — but it is engineered to activate three receptors rather than one or two. In clinical trials it is administered as a once-weekly subcutaneous injection and has been studied in research on obesity, type 2 diabetes, and metabolic-associated fatty liver disease. Critically, retatrutide is not approved by the FDA or any major regulator. It is still moving through clinical development, so anything sold as retatrutide today is unapproved and most often labeled research-only — not a prescription medication you can fill at a pharmacy.
How retatrutide is thought to work
Retatrutide is described as a triple-hormone-receptor agonist: a single molecule engineered to mimic three of the body's own metabolic signals. The GLP-1 component is associated with slowed gastric emptying and reduced appetite, similar to semaglutide. The GIP component adds a second incretin signal involved in glucose handling — the same dual mechanism studied with tirzepatide. The third arm is what distinguishes retatrutide: it also engages the glucagon receptor. While glucagon is commonly associated with raising blood sugar, researchers hypothesize that within this balanced combination its role relates to increasing energy expenditure, while the GLP-1 and GIP arms are associated with glucose regulation. This is the leading hypothesis from the published research, not a settled fact, and it describes a mechanism studied in trials rather than an outcome for any individual.
Areas of research interest
- Obesity and weight management — the focus of its largest published trial
- Type 2 diabetes and glucose control — studied in a separate phase 2 program
- Metabolic-associated fatty liver disease (MASLD/MASH) — examined in an early phase 2a trial
- Triple-agonism as a pharmacological concept — how combining GIP, GLP-1, and glucagon differs from single- or dual-agonist molecules
- Comparison with tirzepatide and semaglutide as subjects of metabolic-peptide research
Side effects & safety
The safety picture for retatrutide comes from clinical trials and is still early — there is no long-term real-world safety record. The most commonly reported adverse events in the obesity and diabetes trials were gastrointestinal: nausea, diarrhea, vomiting, and constipation. These were dose-related, mostly mild to moderate, and occurred largely during dose escalation. Trials also reported dose-dependent increases in resting heart rate that peaked around 24 weeks and then declined, plus a notable rate of dysesthesia (altered skin sensation, such as tingling or hypersensitivity) at the highest doses. As with other incretin agents, broader class risks — pancreatitis, gallbladder issues, and a boxed thyroid-tumor warning carried by approved GLP-1 drugs — are why this category is prescription-only where it is approved at all. Retatrutide itself is not approved, its long-term safety is unknown, and research-grade material has no quality oversight. None of this is medical advice; consult a qualified licensed provider about your own situation.
Retatrutide vs tirzepatide
| Retatrutide | Tirzepatide | |
|---|---|---|
| Receptors targeted | GIP + GLP-1 + glucagon (triple agonist) | GIP + GLP-1 (dual agonist) |
| Developer / code | Eli Lilly (LY3437943) | Eli Lilly (marketed as Mounjaro / Zepbound) |
| Approval status | Investigational — not FDA-approved; in trials | FDA-approved prescription medication |
| Notable extra signal | Glucagon arm studied for energy expenditure | No glucagon activity |
Regulatory status
Retatrutide is not approved by the FDA or any other major regulator. As of 2026 it remains in clinical trials, and there is no approved pharmacy product. Material sold under its name is unapproved and is typically marketed as 'research only / not for human use,' meaning no regulator has verified its identity, purity, sterility, or dosage. PepEasy does not sell peptides, endorse vendors, or advise on obtaining them. The legality and risk of any such material are matters to discuss with a qualified licensed provider; this page is educational and is not medical advice.
Frequently asked
Is retatrutide a steroid?+
No. Retatrutide is a peptide that mimics gut and metabolic hormones (GIP, GLP-1, and glucagon). It is not an anabolic steroid and does not work like one — research interest centers on appetite, glucose control, and energy expenditure.
Is retatrutide FDA approved?+
No. As of 2026 retatrutide is not approved by the FDA or any major regulator — it remains in clinical trials. Anything sold under its name today is unapproved and usually labeled research-only / not for human use.
What are retatrutide's side effects?+
In clinical trials the most commonly reported events were gastrointestinal — nausea, diarrhea, vomiting, and constipation — mostly mild to moderate and concentrated during dose escalation. Trials also reported dose-dependent heart-rate increases and, at higher doses, dysesthesia (altered skin sensation). Long-term safety is unknown because the drug is still in development.
How does retatrutide compare to tirzepatide?+
Tirzepatide is a dual GIP/GLP-1 agonist that is FDA-approved; retatrutide adds a third receptor (glucagon) and is still investigational. They have not been compared head-to-head in a large trial, and an approved drug is not the same as one still being tested. This is descriptive information, not a recommendation.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more